Literature DB >> 18440580

First and second-order motion perception after focal human brain lesions.

Matthew Rizzo1, Mark Nawrot, Jondavid Sparks, Jeffrey Dawson.   

Abstract

Perception of visual motion includes a first-order mechanism sensitive to luminance changes and a second-order motion mechanism sensitive to contrast changes. We studied neural substrates for these motion types in 142 subjects with visual cortex lesions, 68 normal controls and 28 brain lesion controls. On first-order motion, the visual cortex lesion group performed significantly worse than normal controls overall and in each hemifield, but second-order motion did not differ. Only one individual showed a selective second-order motion deficit. Motion deficits were seen with lesions outside the small occipito-temporal region thought to contain a human homolog of motion processing area MT (V5), suggesting that many areas of human brain process visual motion.

Entities:  

Mesh:

Year:  2008        PMID: 18440580      PMCID: PMC3169341          DOI: 10.1016/j.visres.2008.03.005

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  35 in total

1.  DISTURBANCES OF VISION BY CEREBRAL LESIONS.

Authors:  G Holmes
Journal:  Br J Ophthalmol       Date:  1918-07       Impact factor: 4.638

2.  Detection and discrimination of first- and second-order motion in patients with unilateral brain damage.

Authors:  M W Greenlee; A T Smith
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

3.  Regional cerebral correlates of global motion perception: evidence from unilateral cerebral brain damage.

Authors:  L M Vaina; A Cowey; R T Eskew; M LeMay; T Kemper
Journal:  Brain       Date:  2001-02       Impact factor: 13.501

4.  Motion selectivity in macaque visual cortex. III. Psychophysics and physiology of apparent motion.

Authors:  W T Newsome; A Mikami; R H Wurtz
Journal:  J Neurophysiol       Date:  1986-06       Impact factor: 2.714

5.  Color perception profiles in central achromatopsia.

Authors:  M Rizzo; V Smith; J Pokorny; A R Damasio
Journal:  Neurology       Date:  1993-05       Impact factor: 9.910

6.  GABA and its agonists improved visual cortical function in senescent monkeys.

Authors:  Audie G Leventhal; Yongchang Wang; Mingliang Pu; Yifeng Zhou; Yuanye Ma
Journal:  Science       Date:  2003-05-02       Impact factor: 47.728

Review 7.  Comparative mapping of higher visual areas in monkeys and humans.

Authors:  Guy A Orban; David Van Essen; Wim Vanduffel
Journal:  Trends Cogn Sci       Date:  2004-07       Impact factor: 20.229

8.  Visual motion perception after brain damage: II. Deficits in form-from-motion perception.

Authors:  T Schenk; J Zihl
Journal:  Neuropsychologia       Date:  1997-09       Impact factor: 3.139

9.  Visual motion perception after brain damage: I. Deficits in global motion perception.

Authors:  T Schenk; J Zihl
Journal:  Neuropsychologia       Date:  1997-09       Impact factor: 3.139

10.  Motion perception deficits from midline cerebellar lesions in human.

Authors:  M Nawrot; M Rizzo
Journal:  Vision Res       Date:  1995-03       Impact factor: 1.886

View more
  3 in total

1.  Direction-selective patterns of activity in human visual cortex suggest common neural substrates for different types of motion.

Authors:  Sang Wook Hong; Frank Tong; Adriane E Seiffert
Journal:  Neuropsychologia       Date:  2011-09-17       Impact factor: 3.139

2.  Functional and anatomical profile of visual motion impairments in stroke patients correlate with fMRI in normal subjects.

Authors:  Lucia M Vaina; Elif M Sikoglu; Sergei Soloviev; Marjorie LeMay; Salvatore Squatrito; Gabriella Pandiani; Alan Cowey
Journal:  J Neuropsychol       Date:  2009-10-08       Impact factor: 2.864

3.  The neural network for tool-related cognition: An activation likelihood estimation meta-analysis of 70 neuroimaging contrasts.

Authors:  Ryo Ishibashi; Gorana Pobric; Satoru Saito; Matthew A Lambon Ralph
Journal:  Cogn Neuropsychol       Date:  2016-06-30       Impact factor: 2.468

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.